Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for tuberculosis
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on tuberculosis or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on tuberculosis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via firstname.lastname@example.org
Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis 23927582 2013 10 02 2013 11 26 2014 11 20 1535-4970 188 7 2013 Oct 01 American journal of respiratory and critical care medicine Am. J. Respir. Crit. Care Med. Comparison of levofloxacin versus moxifloxacin for multidrug-resistant tuberculosis. 858-64 10.1164/rccm.201303-0604OC Levofloxacin (LFX) and moxifloxacin (MXF) are the two most frequently recommended fluoroquinolones for treatment of patients (...) with multidrug-resistant tuberculosis (MDR-TB). However, studies comparing the effectiveness of LFX and MXF among patients with MDR-TB are lacking. To compare the effectiveness of LFX and MXF in terms of culture conversion after 3 months of treatment for MDR-TB. In this prospective multicenter randomized open label trial, we randomly assigned 182 patients with MDR-TB (sensitive to LFX and MXF) to receive either LFX (750 mg/day; 90 patients) or MXF (400 mg/day; 92 patients) with a background drug regimen
Community-based evaluation of immigrant tuberculosis screening using interferon release assays and tuberculin skin testing: observational study and economic analysis Community-based evaluation of immigrant tuberculosis screening using interferon release assays and tuberculin skin testing: observational study and economic analysis Community-based evaluation of immigrant tuberculosis screening using interferon release assays and tuberculin skin testing: observational study and economic analysis (...) of latent tuberculosis infection in immigrants aged 16 and above. The authors concluded that use of a single-step interferon gamma release assay at intermediate screening thresholds was safe and cost-effective without the need for port-of-arrival chest x-ray. Reporting and methodology were generally good. The conclusions made are appropriate but uncertainty remains around many of the key assumptions/parameters. Type of economic evaluation Cost-effectiveness analysis Study objective The objective
Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper 23349445 2013 08 01 2014 03 20 2017 02 20 1399-3003 42 2 2013 Aug The European respiratory journal Eur. Respir. J. Dried plasma spots in the diagnosis of tuberculosis: IP-10 release assay on filter paper. 495-503 10.1183/09031936.00129412 Interferon (IFN)-γ release assays (IGRAs) are probably the most accurate tests for the detection of latent Mycobacterium tuberculosis infection, but IGRAs are labour (...) on a training cohort comprising 60 tuberculosis (TB) patients and 59 healthy controls. Diagnostic accuracy was assessed in a validation cohort comprising 78 TB patients and 98 healthy controls. Plasma was measured in Spain and DPS samples were sent to Denmark using the conventional postal service for analysis. IP-10 was readily detectable in both plasma and DPS, and correlation was excellent (r(2) = 0.95). QuantiFERON-TB Gold In-Tube (QFT-TB) and IP-10 in DPS and plasma rendered comparable sensitivity (78
Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. BACKGROUND: The Xpert MTB/RIF test for tuberculosis is being rolled out in many countries, but evidence is lacking regarding its implementation outside laboratories, ability to inform same-day treatment decisions at the point of care, and clinical effect on tuberculosis-related morbidity. We aimed to assess (...) the feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing at primary-care health-care facilities in southern Africa. METHODS: In this pragmatic, randomised, parallel-group, multicentre trial, we recruited adults with symptoms suggestive of active tuberculosis from five primary-care health-care facilities in South Africa, Zimbabwe, Zambia, and Tanzania. Eligible patients were randomly assigned using pregenerated tables to nurse-performed Xpert MTB/RIF at the clinic or sputum smear
Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis Systematic review and meta-analysis of the current evidence on the duration of protection by bacillus Calmette-Guérin vaccination against tuberculosis Journals Library An error has occurred in processing the XML document An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry
Effect of household and community interventions on the burden of tuberculosis in southern Africa: the ZAMSTAR community-randomised trial. BACKGROUND: Southern Africa has had an unprecedented increase in the burden of tuberculosis, driven by the HIV epidemic. The Zambia, South Africa Tuberculosis and AIDS Reduction (ZAMSTAR) trial examined two public health interventions that aimed to reduce the burden of tuberculosis by facilitating either rapid sputum diagnosis or integrating tuberculosis (...) and HIV services within the community. METHODS: ZAMSTAR was a community-randomised trial done in Zambia and the Western Cape province of South Africa. Two interventions, community-level enhanced tuberculosis case-finding (ECF) and household level tuberculosis-HIV care, were implemented between Aug 1, 2006, and July 31, 2009, and assessed in a 2×2 factorial design between Jan 9, 2010, and Dec 6, 2010. All communities had a strengthened tuberculosis-HIV programme implemented in participating health-care
The Global Drug Facility and its role in the market for tuberculosis drugs. Universal access to high-quality treatment is central to the Global Plan to Stop TB. The Global Drug Facility (GDF) was launched in 2001 to help to achieve this goal, through services including the supply of affordable, quality-assured drugs to countries in need. We assess the scale of GDF drug supplies worldwide and find that the GDF commands a substantial proportion of the market for drugs for first-line and second
Action to Stop Smoking in Suspected Tuberculosis (ASSIST) in Pakistan: A Cluster Randomized, Controlled Trial. BACKGROUND: Tobacco use is responsible for a large proportion of the total disease burden from tuberculosis. Pakistan is one of the 10 high-burden countries for both tuberculosis and tobacco use. OBJECTIVE: To assess the effectiveness of a behavioral support intervention and bupropion in achieving 6-month continuous abstinence in adult smokers with suspected pulmonary tuberculosis (...) . DESIGN: Cluster randomized, controlled trial. (Current Controlled Trials: ISRCTN08829879) SETTING: Health centers in the Jhang and Sargodha districts in Pakistan. PATIENTS: 1955 adult smokers with suspected tuberculosis. INTERVENTION: Health centers were randomly assigned to provide 2 brief behavioral support sessions (BSS), BSS plus 7 weeks of bupropion therapy (BSS+), or usual care. MEASUREMENTS: The primary end point was continuous abstinence at 6 months after the quit date and was determined
Rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv) - initial treatment of tuberculosis Published 13 May 2013 Statement of Advice: rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv®) Film-coated Tablets (No: 876/13) Genus Pharmaceuticals 05 April 2013 ADVICE: in the absence of a submission from the holder of the marketing authorisation rifampicin, isoniazid, pyrazinamide, ethambutol hydrochloride (Voractiv®) is not recommended for use within NHS (...) Scotland. Indication under review: initial treatment of tuberculosis according to World Health Organisation (WHO) guidelines. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. BACKGROUND: BCG vaccination provides incomplete protection against tuberculosis in infants. A new vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective efficacy of BCG. We aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis (...) followed up infants every 3 months for up to 37 months. The primary study outcome was safety (incidence of adverse and serious adverse events) in all vaccinated participants, but we also assessed efficacy in a protocol-defined group of participants who received at least one dose of allocated vaccine. The primary efficacy endpoint was incident tuberculosis incorporating microbiological, radiological, and clinical criteria, and the secondary efficacy endpoint was M tuberculosis infection according
Cost-effectiveness of various tuberculosis control strategies in Thailand Cost-effectiveness of various tuberculosis control strategies in Thailand Cost-effectiveness of various tuberculosis control strategies in Thailand Hunchangsith P, Barendregt JJ, Vos T, Bertram M Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. CRD summary The objective was to estimate the cost-effectiveness of different tuberculosis control strategies in Thailand. The authors concluded that due to the large uncertainty it was not possible to determine whether directly observed treatment was cost-effective when compared to self-administered treatment. Study methodology was of adequate quality. Methods and results were well reported. Given the limitations
Annals of Internal Medicine Article Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis : Predictors and Relationship to Treatment Outcome Annals of Internal Medicine Artic... preview & related info | Mendeley E-mail address Password ( ) Remember me …or sign in with Search Main Navigation › Short URL Annals of Internal Medicine ( 2000 ) Volume: 144 , Issue: 3 , Publisher: Am Coll Physicians , Pages: 650-659 ISSN: 15393704 PubMed: Available from or Find this paper at: Abstract (...) . Related papers Timothy H Holtz , Maya Sternberg , Steve Kammerer , Kayla F Laserson , Vija Riekstina , Evija Zarovska , et al. in Annals of Internal Medicine (2006) 10 readers A U S Population-based Survey , Philip L Graham III , Susan X Lin , Elaine L Larson in Annals of Internal Medicine (2006) 114 readers F Qazi , U Khan , S Khowaja , M Javaid , A Ahmed , N Salahuddin , et al. in The international journal of tuberculosis and lung disease the official journal of the International Union against
Systematic screening for active tuberculosis: principles and recommendations WHO | Systematic screening for active tuberculosis: principles and recommendations Access Search Search the Navigation Language Tuberculosis (TB) Menu Systematic screening for active tuberculosis: principles and recommendations WHO has developed guidelines on systematic screening for active tuberculosis (TB) based on a thorough review of available evidence. Early detection of TB is essential to further improve health
Nutritional care and support for patients with tuberculosis WHO | Nutritional care and support for patients with tuberculosis Access Search Search the Navigation Language Nutrition Menu Nutritional care and support for patients with tuberculosis Guideline Authors : World Health Organization Publication details Number of pages : 54 Publication date : 2013 Languages : English ISBN : 978 92 4 150641 0 Downloads pdf, 596kb pdf, 334kb Overview This guideline provides guidance on the principles (...) and evidence-informed recommendations on the nutritional care and support for patients with tuberculosis. Undernutrition increases the risk of tuberculosis and in turn tuberculosis can lead to malnutrition. Undernutrition is therefore highly prevalent among people with tuberculosis. It has been demonstrated that undernutrition is a risk factor for progression from tuberculosis infection to active tuberculosis disease and that undernutrition at the time of diagnosis of active tuberculosis is a predictor
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. 23391465 2013 06 17 2013 06 27 2016 11 22 1474-547X 381 9871 2013 Mar 23 Lancet (London, England) Lancet Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. 1021-8 BCG vaccination provides incomplete protection against tuberculosis in infants. A new (...) vaccine, modified Vaccinia Ankara virus expressing antigen 85A (MVA85A), was designed to enhance the protective efficacy of BCG. We aimed to assess safety, immunogenicity, and efficacy of MVA85A against tuberculosis and Mycobacterium tuberculosis infection in infants. In our double-blind, randomised, placebo-controlled phase 2b trial, we enrolled healthy infants (aged 4–6 months) without HIV infection who had previously received BCG vaccination. We randomly allocated infants (1:1), according